The company's platform enables biologists to develop processes by running dozens of cell culture conditions in parallel with extreme process control, making it easier to scale up cells for manufacturing at an affordable cost. MicrofluidX's focus is on autologous cell and gene therapy, where the platform's benefits are particularly significant. By addressing the challenges of process control, scalability, and cost, MicrofluidX is helping to make bioprocessing more accessible and affordable for cell and gene therapy.